Back to discover
Disease

Ventricular Fibrillation

Late-stage therapeutic developmentEmerging research
MeSHVentricular Fibrillation
1
Publications
11
Clinical trials
2005
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
Results expected Q2 20272026-07-07
Upcoming trial readoutImportant
Investigation of RIsk Factors in Out-of-hospital-cardiac-arrest Patients, and MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
Results expected Q4 20322026-02-12
Clinical Milestones3View
Results expected 3
Activity timeline3

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Dronedaroneapproved

Approval — Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in… (2009)

Clinical trials

9 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
11
All trials
3
Active
7
Late-stage
6
Completed
Late-stage studies

Investigation of RIsk Factors in Out-of-hospital-cardiac-arrest Patients, and MEdical Treatment in Idiopathic Ventricular Fibrillation Patients

Phase 4 · Recruiting · Bo Gregers Winkel

CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)

Phase 4 · Recruiting · Unity Health Toronto

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

Phase 3 · Recruiting · Ottawa Heart Institute Research Corporation

IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients

Phase 4 · Completed · Biotronik SE & Co. KG

ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy

Phase 4 · Completed · Medtronic Cardiac Rhythm and Heart Failure

Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study)

Phase 4 · Completed · Mayo Clinic
Recently completed

Acute Feasibility Investigation of a New S-ICD Electrode Arrangement for Reduction of Defibrillation Energies

N/A · Completed · Boston Scientific Corporation

Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction

N/A · Completed · Boston Scientific Corporation

IN-TIME: Influence of Home Monitoring on the Clinical Status of Heart Failure Patients

Phase 4 · Completed · Biotronik SE & Co. KG

Reduction And Prevention of Tachyarrhythmias and Shocks Using Reduced Ventricular Pacing With Atrial Algorithms (The RAPTURE Study)

Phase 4 · Completed · Mayo Clinic

ADVANCE CRT - D: ATP Delivery for Painless ICD Therapy

Phase 4 · Completed · Medtronic Cardiac Rhythm and Heart Failure

Antiarrhythmics Versus Implantable Defibrillators (AVID)

Phase 3 · Completed · National Heart, Lung, and Blood Institute (NHLBI)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2009emaApproval — Dronedarone· Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered. Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes1
  • Electrocardiography1
Leading journals1
  • Circulation1
Leading researchers8
  • Antzelevitch C1
  • Borggrefe M1
  • Brugada J1
  • Brugada P1
  • Brugada R1
  • Corrado D1
  • Gussak I1
  • LeMarec H1
Affiliations (unnormalised)1
  • Masonic Medical Research Laboratory1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.

Identifiers
MeSHVentricular Fibrillation
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.